NCT07850284Recruiting
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Source: ClinicalTrials.gov · Last updated 30 Sept 2026
Brief summary (registry, in English)
This study evaluates whether daily SMS-based (text messages) symptom monitoring is feasible and acceptable in patients who are undergoing treatment for multiple myeloma (MM) or systemic light chain amyloidosis (AL), and whether it can help in early identification of symptoms that may require clinical attention.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 150 (estimated)
- First submitted
- 23 Sept 2026
- Start date
- 25 Aug 2026
- Primary completion date
- 25 Aug 2028
- Lead sponsor
- Mayo Clinic
- Diseases
- Amyloidosis, Multiple myeloma
- NCT number
- NCT07850284
What you commit to
- Study type: Observational
- Planned participants: 150
- From 25 Aug 2026 to the primary completion date, 25 Aug 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Not able to give informed consent
Who the study is looking for
- Age \>= 18 years
- Diagnosis of MM or AL based on IMWG diagnostic criteria
- Planned to start a new treatment within 14 days (+/-7 days)
- Able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.